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Abstract
Background: MI-319 is a synthetic small molecule designed to target the MDM2-P53 interaction.
It is closely related to MDM2 antagonists MI-219 and Nutlin-3 in terms of the expected working
mechanisms. The purpose of this study was to evaluate anti-lymphoma activity of MI-319 in WSU-
FSCCL, a B-cell follicular lymphoma line. For comparison purpose, MI-319, MI-219 and Nutlin-3
were assessed side by side against FSCCL and three other B-cell hematological tumor cell lines in
growth inhibition and gene expression profiling experiments.
Results: MI-319 was shown to bind to MDM2 protein with an affinity slightly higher than that of
MI-219 and Nutlin-3. Nevertheless, cell growth inhibition and gene expression profiling
experiments revealed that the three compounds have quite similar potency against the tumor cell
lines tested in this study. In vitro, MI-319 exhibited the strongest anti-proliferation activity against
FSCCL and four patient cells, which all have wild-type p53. Data obtained from Western blotting,
cell cycle and apoptosis analysis experiments indicated that FSCCL exhibited strong cell cycle arrest
and significant apoptotic cell death; cells with mutant p53 did not show significant apoptotic cell
death with drug concentrations up to 10 μM, but displayed weaker and differential cell cycle
responses. In our systemic mouse model for FSCCL, MI-319 was tolerated well by the animals,
displayed effectiveness against FSCCL-lymphoma cells in blood, brain and bone marrow, and
achieved significant therapeutic impact (p < 0.0001) by conferring the treatment group a > 28%
(%ILS, 14.4 days) increase in median survival days.
Conclusion: Overall, MI-319 probably has an anti-lymphoma potency equal to that of MI-219 and
Nutlin-3. It is a potent agent against FSCCL in vitro and in vivo and holds the promises to be
developed further for the treatment of follicular lymphoma that retains wild-type p53.
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Background
Follicular lymphoma is a slow growing B-cell lymphoma
and is the second most common type of non-Hodgkin's
lymphoma (NHL), which is expected to have more than
66,000 new cases in the USA in 2008 [1]. Despite
improvement of survival rates in recent years [2,3], follic-
ular lymphoma remains incurable due mainly to limita-
tions of the current first-line standard of treatment, which
usually involves concomitant administration of human-
ized anti-CD20 monoclonal antibody rituximab and a
chemotherapy regimen [4]. In the pivotal clinical trial that
led to the approval of rituximab for clinical use in the
USA, only 48% of patients with relapsed follicular lym-
phoma responded [5]. Therefore, better therapeutics is
needed to further improve the outcome of afflicted
patients.
A growing number of recent reports suggest that small
molecule inhibitors targeting the MDM2-p53 interaction
may represent very promising, specific and novel thera-
peutics against various types of cancers [6-9]. The p53
gene is an important tumor suppressor. It can promote
cell cycle arrest by up-regulating the expression of genes
involved in cell cycle control, such as p21WAF1 [10,11];
and can also promote apoptosis, possibly by the up-regu-
lation of pro-apoptotic genes, such as Bax and PUMA [12-
14]. Among all the cancer patients, approximately half of
them have mutated or deleted p53 gene, which leads to
defective p53 protein or complete missing of functional
p53 protein [15,16]. Among the remaining patients with
wild-type p53 gene, functional p53 protein is quickly
degraded after protein translation, primarily through
direct interaction with the MDM2 protein [17]. Thus,
using small molecules to block the MDM2-p53 interac-
tion is an attractive approach to stabilize functional p53
protein and restore its anti-tumor activity in tumors with
wild-type p53 gene.
Unlike in many solid tumors, alterations of the p53 gene
are far less common in hematological malignancies (gen-
erally < 15%) [18]. Therefore, small-molecule inhibitors
that interrupt the MDM2-p53 interaction might represent
a new therapeutic strategy for the treatment of most
patients with this kind of disease. Previous studies dem-
onstrated that a different inhibitor of MDM2, Nutlin-3, is
indeed able to efficiently induce apoptosis in B-cell
chronic lymphocytic leukemia (B-CLL) [19-24]. To our
knowledge, however, there are no reports so far on the
studies of this kind of small-molecule inhibitors against
follicular lymphoma. In the present study, we report on
the evaluation of a new inhibitor of the MDM2-p53 inter-
action, named MI-319, against a follicular small cleaved
B-cell lymphoma line (FSCCL) [25]in vitro by using cul-
tured cells and in vivo by using a systemic model in mice
with severe combined immunodeficiency (SCID). MI-319
is closely related to MDM2 antagonists MI-219 [8] and
Nutlin-3 [6] in terms of the expected main working mech-
anisms. For comparison purpose, we also assessed these
three compounds side by side against FSCCL and three
other B-cell hematological tumor cell lines in growth inhi-
bition and gene expression profiling experiments.
Results
MI-319 binds to MDM2 protein with high affinity
MI-319 has a chemical structure very similar to that of MI-
219 (Fig. 1A). The fluorescence polarization-based com-
petitive binding assay determined that MI-319 binds to
recombinant human MDM2 protein with a Ki value of 9.6
± 3.9 nmol/L, which is lower than the Ki values of 13.3 ±
1.8 nmol/L and 36.0 ± 9.0 nmol/L determined for MI-219
(Fig. 1B) and Nutlin-3 [8], respectively. Therefore, MI-319
binds to human MDM2 protein with an affinity slightly
higher than that of MI-219 and Nutlin-3. When compared
with p53 protein - a natural MDM2 binding target, it
appeared that both MI-319 and MI-219 were over 500
times more potent than a natural p53 peptide in binding
to MDM2 under the same assay conditions (Fig. 1B).
FSCCL cell growth can be effectively inhibited by MI-319, 
MI-219 and Nutlin-3
Because MDM2 antagonists such as MI-319 were expected
to work mainly by restoring the activities of functional
p53 protein, DNA sequencing was carried out first to
determine the mutation status of p53 in the cells studied.
P53 full-length coding cDNA sequences were sequenced
for the four B-cell lines (WSU-FSCCL, WSU-WM, RL and
WSU-DLCL2), whereas p53 genomic DNA sequences cov-
ering exons 5-9 were sequenced for four patient cells.
Sequencing results are summarized in Table 1. We have
used these four cell lines since they represent a wide spec-
trum of b-cell lineage tumors: (a) WSU-FSCCL [represent-
ing follicular low grade non-Hodgkin's lymphoma type
that is wt-p53]; (b) WSU-WM [representing plasmacytoid
type that is mut-p53]; (c) RL representing diffuse large B-
cell lymphoma, mut-p53; (d) WSU-DLCL2 [representing
diffuse, Intermediate grade non-Hodgkin's lymphoma
mut-p53].
Cell growth was examined by MTT assay [26]. As shown
in Fig. 2, MI-319, MI-219 and Nutlin-3 demonstrated sim-
ilar potency and all effectively inhibited the growth of
FSCCL in a dose-dependent manner. For a 48-hour expo-
sure, the concentration that leads to 50% inhibition of
proliferation (IC50) of FSCCL is estimated to be 2.5 μM
for all three compounds. For the three cells with mutant
p53, IC50 can not be determined yet with drug concentra-
tions up to 20 μM. Therefore, the three compounds exhib-
ited approximately 10-fold selectivity in cells with wild-
type p53 over cells with mutant p53. Interestingly, the
three cells with mutant p53 responded differentially to all
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Chemical structure of MI-319 and MI-219 and MDM2 protein binding assayFigure 1
Chemical structure of MI-319 and MI-219 and MDM2 protein binding assay. (A), Chemical structure of MI-319 and 
MI-219. (B), Fluorescence polarization-based MDM2 binding assay. The binding affinities (Ki values) were determined by a com-
petitive fluorescence polarization-based binding assay using recombinant His-tagged MDM2 (amino acids 1-118) and PMDM6-F 
(5-FAM-βAla-βAla-Phe-Met-Aib-pTyr-(6-Cl-L-Trp)-Glu-Ac3c-Leu-Asn-NH2), a fluorescently labeled high-affinity p53-based 
peptide.
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the three compounds. WM exhibited the strongest
response, whereas DLCL2 exhibited the weakest response
(Fig. 2).
In order to get a sense of clinical relevance of MI-319, we
isolated, cultured and treated mononuclear cells from
four B-cell lymphoma patients. As shown in Fig. 3, MI-
319 showed significant cytotoxic effect on all four primary
cultures.
FSCCL cells exhibited increased protein levels of p53, 
MDM2, p21 and cleaved PARP after treatment with MI-
319, MI-219 or Nutlin-3
Treatment with MI-319, MI-219 or Nutlin-3 for 12 hours
led to similar increase in protein levels of p53, MDM2,
p21 and cleaved PARP in FSCCL cells in a dose-dependent
manner (Fig. 4). The levels of Bax and PUMA, however,
were not affected by the treatments. In WM cells, which
have R213Q p53 mutation, MI-319, MI-219 and Nutlin-3
induced increased protein levels of p53, MDM2 and p21,
but not that of Bax, PUMA and cleaved PARP (Fig. 4). In
RL and DLCL2 cells, treatment with the three compounds
did not induce any significant protein level changes
among the genes tested (Fig. 4).
MI-319 induced differential cell cycle arrest responses 
among FSCCL, WM, RL and DLCL2 cells
As shown in Fig. 5, treating FSCCL cells with 10 μM of MI-
319 for 24 hours increased G0-G1 cells by approximately
24% and decreased S and G2-M cells by approximately
14% and 10%, respectively. In comparison, WM, RL and
DLCL2 cells exhibited weaker and differential responses.
In WM, G0-G1 cells increased by approximately 19%,
while S and G2-M cells decreased by approximately 17%
and 2%, respectively (Fig. 5). In RL, G0-G1 cells increased
by approximately 5%, while S and G2-M cells decreased
by approximately 3% and 2%, respectively (Fig. 5). In
DLCL2, G0-G1 cells increased by approximately 13%,
while S and G2-M cells decreased by approximately 4%
and 9%, respectively (Fig. 5).
MI-319 induces apoptotic cell death only in FSCCL cells
Although the protein levels of pro-apoptotic p53 target
genes such as Bax and PUMA are not affected by treatment
with MI-319 (Fig. 4), in FSCCL cells however, there was a
dose-dependent increase in cleaved PARP, which is one of
the hallmarks of apoptotic cell death. To further investi-
gate whether apoptotic mechanisms were involved, we
analyzed cell death by Annexin V staining and Tunnel
assay. As shown in Fig. 6, both experiments revealed that
treating cells with 10 μM of MI-319 for 24 hours induced
significant apoptotic cell death only in FSCCL cells.
MI-319 has significant anti-lymphoma activity in FSCCL 
systemic SCID mouse model
MI-319 was administered orally to the animals at 300 mg/
kg twice a day (BID) for 7 days. The dose schedule was
adopted from a previous study with MI-219 [8]. At this
dose, MI-319 displayed no major adverse effect (> 15%)
on body weight gain by the treated animals (Fig. 7A), sug-
gesting it was tolerated well. After the administration of
MI-319 was stopped, all animals gained weight (Fig. 7A).
At day 51, when first control mouse died, one mouse from
the treatment group was sacrificed and tissue samples
were harvested. The effectiveness of MI-319 was first dem-
onstrated by pathological examination of stained mouse
tissues. As shown in Fig. 7B, blood, brain and bone mar-
row from the control mouse showed heavy involvement
by lymphoma cells. In contrast, MI-319-treated mouse
showed normal peripheral blood, brain and bone marrow
with no apparent lymphoma involvement (Fig. 7B).
Spleen and liver sections were also examined and neither
control nor MI-319-treated mouse showed lymphoma
involvement (Fig. 7B). Between days 51 and 52 post
tumor cell inoculation, all seven control mice succumbed
to the disease, with a median survival of 51.6 days (Fig.
7C). By contrast, until up to day 70 post tumor cell inoc-
ulation, only five out of seven MI-319-treated mice died,
indicating a median survival of over 66.0 days. Thus, treat-
ment with MI-319 conferred a > 28% (% ILS, 14.4 days)
increase in median survival days and has statistically sig-
nificant therapeutic impact (p < 0.0001). For the one
remaining treated mouse, it remained alive after 90 days
and appeared to achieve a complete cure.
Discussion
Follicular lymphoma is the second most common type of
NHL, which has increased incidence over the past three
decades and is now the fifth most common cancer in the
United States [1]. Current therapeutic tools for follicular
lymphoma, such as monoclonal antibodies, radio-immu-
notherapy, vaccines and chemotherapeutic agents, all
have limitations [27]. In an attempt to search for a tar-
geted and less toxic agent that can be administered orally,
we evaluated the anti-lymphoma activity of MI-319 in a
follicular small cleaved cell lymphoma cell line estab-
lished in our laboratory. Data obtained in our studies is
encouraging and is consistent with the following state-
ments: i) MI-319 is able to bind to MDM2 protein with a
high affinity that is over 500-fold more potent than a nat-
Table 1: Summary of cell P53 status
Cell p53 mutation status
FSCCL wild-type
WM R213Q
RL A138P
DLCL2 A248Q
BP071708 wild-type
RM072307 wild-type
CH012306 wild-type
JC012706 wild-type
Molecular Cancer 2009, 8:115 http://www.molecular-cancer.com/content/8/1/115
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ural p53 peptide; ii) MI-319 effectively inhibited prolifer-
ation of FSCCL cell (p53 wild-type) in vitro, with IC50
value of 2.5 μM for 48-hour treatment; iii) Inhibition of
FSCCL cell proliferation by MI-319 involves induction of
both cell cycle arrest and apoptotic death; iv) MI-319 dis-
played potent anti-tumor efficacy in the FSCCL-SCID
mouse model.
MI-319 was designed to stabilize p53 protein in cells by
blocking the MDM2-p53 interaction. Although many
genes in addition to p53 are usually altered in tumors,
recent studies suggest that restoring p53 function alone is
sufficient to cause regression of established sarcomas,
lymphomas, and liver tumors in mice [28-30]. Therefore,
restoring functional p53 activity by using small mole-
cules, such as MI-319, to block MDM2-p53 interaction
and stabilize p53 protein is an attractive pharmacological
approach. Since the discovery of the Nutlins [6], there has
been a great deal of interest in the evaluation of small-
molecule inhibitors of the MDM2-p53 interaction against
various types of cancer [9]. Currently there are two major
classes of such small-molecule inhibitors. One class is rep-
resented by Nutlin-3 [6,31,32]; the other one is repre-
sented by MI-219 [8]. MI-319 is a very close analogue of
MI-219. In our fluorescence polarization-based competi-
tive binding assay, MI-319 exhibited a binding affinity to
human MDM2 protein that is slightly higher than that of
MI-219 and Nutlin-3. Nevertheless, the three compounds
have similar potency against the cells tested in this report
in terms of growth inhibition and regulation of expression
of p53 target genes, such as MDM2, p21, Bax and PUMA.
Therefore, we believe that MI-319, MI-219 and Nutlin-3
Effect of MI-319, MI-219 and Nutlin-3 on cell proliferation in vitroFigure 2
Effect of MI-319, MI-219 and Nutlin-3 on cell proliferation in vitro. Established tumor cell lines. Cells were grown for 
48 hours. The number of viable cells was determined by MTT assay.
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are probably equal as an MDM2 antagonist. In our
remaining cell cycle analysis, apoptotic cell death assays
and animal model studies, we assessed only MI-319 sim-
ply due to availability issues.
One of the mechanisms of MI-219- or Nutlin-3-induced
apoptosis is thought to occur via p53's transcriptional
program by up-regulating the expression of pro-apoptotic
p53 target genes such as Bax and PUMA [8,33,34]. In our
studies, we observed that exposing lymphoma cells to MI-
319 for 24 hours with concentrations up to 10 μM
induced significant apoptotic cell deaths only in FSCCL,
which bears wild-type p53. However, protein levels of nei-
ther Bax nor PUMA were up-regulated by MI-319, MI-219,
or Nutlin-3. We treated FSCCL cells for 24 hours with
higher drug concentrations of 20 and 30 μM and found
that MI-319-induced apoptosis was apparently p53 tran-
scription-independent. At MI-319 concentrations of 20
and 30 μM, FSCCL exhibited decreased proteins levels of
p53 transcriptional target genes, such as MDM2, p21, Bax
and PUMA. However, cleavage of PARP and the number
of TdT-positive cells (apoptotic cells) increased signifi-
cantly in a dose-dependent manner (Fig. 8). It has been
reported by Vaseva et al. that the transcription-independ-
ent mitochondrial p53 program is a major contributor to
Nutlin-induced apoptosis in tumor cells [35]. It appears
Effect of MI-319, MI-219 and Nutlin-3 on cell proliferation in vitroFigure 3
Effect of MI-319, MI-219 and Nutlin-3 on cell proliferation in vitro. Mononuclear cells isolated from lymphoma patients 
- BP071708 is diffuse large B-cell lymphoma (DLCL), RM072307 is marginal zone B-cell lymphoma (MZL), JC012706 is another 
marginal zone B-cell lymphoma (MZL), and CH012306 is small lymphocytic lymphoma (SLL). The number of viable cells was 
determined by trypan blue exclusion test. Data represents mean of three independent experiments. * represents p < 0.05 ** 
represents p < 0.01.
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that Nutlin-induced mitochondrial p53 translocation is
rapid and associated with cytochrome C protein release
that precedes induction of p53 target genes [35]. Further-
more, blocking the transcriptional arm of p53 not only
fails to inhibit, but greatly potentiates Nutlin-induced
apoptosis [35]. We speculate that MI-319-induced apop-
tosis of FSCCL cells may also occur mainly via the tran-
scriptional-independent mitochondrial p53 program.
In our studies, we assessed FSCCL side by side with three
other cells that have mutant p53-WSU-WM (R213Q), RL
(A138P) and WSU-DLCL2 (R248Q). Interestingly, the
cells expressing the three mutants behaved differently in
terms of cell proliferation, cell cycle arrest and expression
of some of p53's target genes, such as MDM2 and p21.
WM responded the strongest among the three and RL and
DLCL2 responded much weaker. Previous reports have
documented that these three p53 mutants still retain
some of wild-type p53 protein's regulatory functions.
When A138P and R248Q mutants were expressed in p53
null cells, it was found that both of them still retain a little
(< 5%) of p53's regulatory activities [36,37]; according to
Gene expression profiling by Western blottingFigur  4
Gene expression profiling by Western blotting. Cells were treated with indicated chemical or equal volume of 100% 
DMSO for 12 hours.
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the studies by Pan et al., the R213Q mutant is still par-
tially functional [38] and therefore probably retains much
more of wild-type p53's regulatory activities. Compared
with wild-type p53, R213Q mutant p53 protein has a
weaker transactivating activity for p21 gene [38]. Our gene
expression profiling data obtained by Western blotting
agreed quite well with this result. Treatment with MI-319,
MI-219 or Nutlin-3 all led to dose-dependent up-regula-
tion of p21 protein in WM cells, but appeared less robust
than that in FSCCL. Overall, it appeared that the different
responses of the three cells with p53 mutants correlated
very well with the level of wild-type p53's regulatory activ-
ities retained by the corresponding p53 mutant proteins.
The main goal of our study is to find a novel agent that
holds promises to make its way into clinical trials for the
treatment of follicular lymphoma. Thus, we tested the
anti-lymphoma activity of MI-319 in vivo by using a sys-
temic FSCCL SCID mouse model. MI-319 given orally for
one week showed no major toxicity, such as > 15% weight
loss in treated animals, whereas the treatment showed a
significant therapeutic impact (p < 0.0001); conferring a
more than 28% (14.4 days) increase in life span (ILS).
Conclusion
Our studies showed that MI-319, MI-219 and Nutlin-3
have similar potency as an MDM2 antagonist. MI-319 has
potent anti-lymphoma activities against FSCCL cells. It
stabilizes p53 protein and induces cell cycle arrest and
apoptosis in follicular lymphoma cells that retain wild-
type p53. When administered orally to the animals, MI-
319 showed significant anti-lymphoma activity. Our
Cell cycle analysisFigure 5
Cell cycle analysis. Cells were treated with MI-319 or equal volume of 100% DMSO for 24 hours. Numbers plotted here are 
the average of at least three independent experiments. * represents p < 0.05 and ** represents p < 0.01.
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results provide confidence towards the development of
MDM2 inhibitors for lymphoma patients in the clinic.
Methods
Chemical synthesis and competitive binding assay
MI-319 and MI-219 were synthesized by using methods
published previously [39]. Nutlin-3 was purchased from
Sigma-Aldrich. For cell culture experiments, MI-319, MI-
219 and Nutlin-3 were dissolved in 100% DMSO to make
10 mM stock solutions which were kept at -70°C. Fluores-
cence polarization-based competitive binding assays were
performed to determine the binding affinity of MI-319
and MI-219 with a recombinant His-tagged MDM2 pro-
tein. The assays were carried out as described previously
[40].
MI-319 induces cell apoptosis in FSCCL cells onlyFigure 6
MI-319 induces cell apoptosis in FSCCL cells only. (A) Cells were stained with Annexin V-FITC and quantification of the 
percentage of apoptotic cells was done with a Coulter EPICS 753 flow cytometer. (B) Tunnel assay. TdT+ cells (apoptotic cells) 
were assessed with a Coulter EPICS 753 flow cytometer. Numbers plotted here are the average of three independent experi-
ments. * represents p < 0.05 and ** represents p < 0.01.
FSCCL (p53 wild-type)
DLCL2 (p53 R248Q)
30.57 + 1.89%1.88 + 0.46%
1.70 + 0.27% 2.98 + 0.22%
0.18 + 0.10% 0.55 + 0.18%
5.01 + 0.32% 4.82 + 0.24%
0 μM                            10 μM                                      0 μM                            10 μM                MI-319
0 μM                            10 μM                                      0 μM                            10 μM                MI-319
WM (p53 R213Q)
RL (p53 A138P)
A
B
0
10
20
30
40
50
60
70
80
90
100
FSCCL WM RL DLCL2
A
po
pt
o
tic
 
Ce
lls
 
(%
)
0 μM
10 μM**   
Molecular Cancer 2009, 8:115 http://www.molecular-cancer.com/content/8/1/115
Page 10 of 14
(page number not for citation purposes)
P53 genomic DNA and full-length cDNA sequencing
Genomic DNAs were extracted by adapting a procedure
described previously [41]. The amount of genomic DNA
was determined by UV absorption at 260 nm. 200 ng was
used in each reaction of PCR amplification. Primers to
amplify exons 5/6, 7, and 8/9 of human p53 and adjacent
intronic sequences were adopted from the literature [24]
with modification of the p53-E5/6-F primer sequence as
5'-ggaggtgcttacgcatgtttg-3'. Amplified PCR products were
analyzed by agarose gel electrophoresis, cleaned with Wiz-
ard SV Gel/PCR Cleanup kit (Promega, Madison, WI), and
sequenced directly. Sequencing was done with the
Applied Biosystems ABI Prism 3700 sequencer (Applied
Survival of FSCCL-SCID mice is prolonged with the treatment of MI-319Figure 7
Survival of FSCCL-SCID mice is prolonged with the treatment of MI-319. (A) Treatment with MI-319 did not result 
in significant body weight changes (> 15%). Wn=mouse body weight at day (n); W4 = mouse body weight at day (4) when the 
administration of MI-319 was started. (B) H&E staining of mouse blood smear and sections of mouse brain, bone marrow, liver, 
and spleen. Arrows in the upper blood panel (untreated) point to lymphocytes, indicating lymphoma involvement. Lower brain 
panel (MI-319-treated) is an example of no involvement by lymphoma. Note the thin meningeal lining of the brain (between 
opposing arrows). In comparison, the upper panel (untreated) shows examples of involvement of the meninges by lymphoma. 
Note the expanded space between the opposing arrows indicative of lymphoma cell infiltration. For the bone marrow (femurs) 
sections, lower panel (MI-319-treated) shows examples of normal marrow and upper panel (untreated) shows examples of 
involvement by WSU-FSCCL (note the cavities filled with lymphocytes). (C) The survival percentage of untreated and MI-319-
treated mice is plotted against days post FSCCL inoculation. The control animals have a median survival day of 51.6, whereas 
the treatment animals have a median survival day of over 66.0. n = 7 for control group, n = 6 for treatment group, p < 0.0001.
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Biosystems, CA). Sequencing reactions were performed
using the ABI BigDye®Terminator v3.1.
In order to sequence full-length p53 cDNA, total RNAs
were isolated from cells using the RNeasy® Isolation Kit
(Qiagen, Valencia, CA). The amount of total RNA was esti-
mated by UV absorption at 260 nm. The extracted RNAs
(2 μg of each sample) were reverse-transcribed with the
ImProm-II(TM) Reverse Transcription System, following
the manufacturer's instructions (Promega, Madison, WI).
PCR reactions were performed subsequently to amply p53
cDNA with an Eppendorf AG Mastercycler (Hamburg,
Germany). Two pairs of primers were used to amplify the
full-length p53 coding cDNA sequence. The sequence of
the primers is as follows: p53-F1/p53-R1 (5'-aagtcta-
gagccaccgtcca-3'/5'-catagggcaccaccacacta-3'), p53-F2/p53-
R2 (5'-gtggaaggaaatttgcgtgt-3'/5'-gtggggaacaagaagtggag-
3'). The PCR products were analyzed by agarose gel elec-
trophoresis, cleaned with Wizard SV Gel/PCR Cleanup kit
(Promega, Madison, WI), and sequenced directly.
MI-319-induced FSCCL apoptotic cell death might be p53 transcription-independentFigure 8
MI-319-induced FSCCL apoptotic cell death might be p53 transcription-independent. (A) FSCCL cells were 
treated for 12 hours and Western blotting experiments were performed to examine the protein levels of p53, MDM2, p21, 
Bax, PUMA and PARP. (B) FSCCL cells were grown for 24 hours after drug treatment and apoptotic cell death was assessed 
with Tunnel assay.
β-actin
Bax
MDM2
P21
P53
Cleaved PARP
Puma α
Full-length PARP
Puma β
0   2.5   5   10   20  30     MI-319 (μM)A
B
30.57 + 1.89%1.88 + 0.46%
0 μM                            10 μM                            30 μM           MI-319
68.36 + 1.46%
Molecular Cancer 2009, 8:115 http://www.molecular-cancer.com/content/8/1/115
Page 12 of 14
(page number not for citation purposes)
Cell culture
Cell lines FSCCL, WM and DLCL2 were established in our
laboratory [25,42,43]. The cell line RL was purchased
from the American Type Culture Collection (ATCC, Rock-
ville, MD, USA). Mononuclear cells were isolated from
four lymphoma patients - BP071708 is diffuse large B-cell
lymphoma (DLCL) intermediate grade; RM072307 is
marginal zone B-cell lymphoma (MZL) low grade;
JC012706 is another marginal zone B-cell lymphoma
(MZL) low grade; and CH012306 is small lymphocytic
lymphoma (SLL) low grade. All patients had stage IV dis-
ease. Lymphoma cells were isolated by Ficoll gradient cen-
trifugation (GE Healthcare, Little Chalfont, United
Kingdom), seeded into growth medium right away or
aliquoted into fetal bovine serum with 10% DMSO and
cryopreserved in liquid nitrogen. Studies involving
human tissues were done according to IRB-approved pro-
tocol and all patients had signed informed consent prior
to tissue procurement. Cells were usually seeded at a den-
sity of 2 × 105 viable cells per ml in 24-well or 6-well cul-
ture plates (Costar, Cambridge, MA), or 10-cm cell culture
dishes (Corning Inc., Corning, NY). All cells were main-
tained in RPMI 1640 medium supplemented with 10%
fetal bovine serum (Hyclone Laboratories, Logan, Utah)
and 1% Penicillin-Streptomycin (Invitrogen, Carlsbad,
CA), at 37°C in a humidified incubator with 5% CO2. The
number of viable cells was determined by trypan blue
exclusion test with trypan blue (0.4%) purchased from
Sigma Chemical Co. (St. Louis, MO) and MTT assay [26].
Statistical analysis was done using the t test (two tailed)
with 95% confidence intervals between treated and
untreated samples. P < 0.05 was used to indicate statistical
significance.
Western blot
Cells were collected by centrifugation, washed twice with
cold PBS, and lysed at 4°C in lysis buffer containing pro-
tease inhibitors as described previously [44]. Total protein
content in lysates was estimated by the Bradford method
[45]. The primary antibodies used in the experiments
included p53 (Cell Signaling, Danvers, MA), MDM2
(R&D System, Minneapolis, MN), p21 (Cell Signaling,
Danvers, MA), Bax (Sigma, St. Louis, MO), PUMA (Sigma,
St. Louis, MO), PARP (Cell Signaling), and β-actin
(Sigma).
Cell cycle analysis
Cells were collected by centrifugation and washed twice
with cold PBS. Cell pellets were resuspended in 0.5 ml of
cold PBS and fixed in 4.5 ml of 70% ethanol and stored at
4°C. On the day of analysis, cells were collected by centrif-
ugation and each pellet was resuspended in 1 ml of stain-
ing buffer, which contains 50 μg/mL of propidium iodide,
100 μg/mL of RNase A, and 0.1% of Triton X-100. The cell
suspensions were incubated in the dark for 30 minutes at
room temperature and subsequently analyzed on a Coul-
ter EPICS 753 flow cytometer for DNA content. The per-
centage of cells in different phases of the cell cycle was
determined using a ModFit 5.2 computer program.
Apoptosis analysis
Apoptotic cell death was determined with two methods:
Annexin V-FITC staining and Tunnel assay. Annexin V-
FITC staining kit and ApoDIRECT In Situ DNA Fragmen-
tation Assay (Tunnel assay) kit were purchased from Bio-
Vision (Mountain View, CA). Experiments were
performed by following the manufacturer's instructions.
Quantifications of the percentage of apoptotic cells were
done with a Coulter EPICS 753 flow cytometer.
FSCCL systemic xenograft model
All animal studies were conducted according to Animal
Investigation Committee (AIC)-approved protocol of
Wayne Sate University. This systemic model was initiated
by injecting 20 × 106 FSCCL cells via the tail vein (iv) of
acclimated 3-4 week old female severe combined immune
deficient mice (ICR-SCID) (Taconic Farms, Germantown,
NY). Animals were monitored daily for changes in weight,
side effects of the treatment or signs of any sickness. 8-10
weeks post inoculation, symptoms such as diarrhea, dehy-
dration, ascites, lethargy, paralysis and/or general weak-
ness became evident, thus animals were euthanized,
tissues such as liver, spleen, bone marrow, lymph nodes,
blood and brain were harvested and subjected to H&E
staining to evaluate pattern of dissemination, involve-
ment and confirmation of engraftment. Engraftment rate
for this model is 100%.
Animal preclinical efficacy trial design
The in vivo anti-tumor activity of MI-319 was assessed
against our FSCCL xenograft model. To ensure random-
ness, 14 animals were combined in a single cage and inoc-
ulated with FSCCL. Seventy-two hours later, mice were
pooled and 2 groups of seven animals each were ran-
domly and unselectively assigned to two interventions;
control and MI-319-treated group. MI-319 was adminis-
tered orally at 300 mg/kg BIDx7.
Percent Increase in Host life Span (%ILS)
%ILS was calculated by subtracting the median day of
death of the treated tumor-bearing mice from median day
of death of the tumor-bearing control divided by the
median day of death of the tumor-bearing control ani-
mals. Statistical analysis of data was carried out with
GraphPad Prism software. Survival distribution of the
treated (T) and control (C) groups was compared using
the log-rank test. In this report, survival was characterized
as the duration of the animal's life span 24-hours after the
initiation of the xenograft until an observed event (eutha-
nasia or death).
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Pathological evaluation of mouse tissues
Necropsy was carried out to determine extent of macro-
scopic lymphoma. Major organs including the brain,
femur (for bone marrow), liver, and spleen were har-
vested for microscopic examination. In addition, periph-
eral blood smears were examined for evidence of
circulating lymphoma cells.
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